Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.

Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ, Siegel BA.

Dis Colon Rectum. 2008 Nov;51(11):1641-8. doi: 10.1007/s10350-008-9420-3. Epub 2008 Aug 6.

2.

Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines.

Vāvere AL, Lewis JS.

Nucl Med Biol. 2008 Apr;35(3):273-9. doi: 10.1016/j.nucmedbio.2007.11.012.

3.

Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).

Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ.

J Nucl Med. 2008 Feb;49(2):201-5. doi: 10.2967/jnumed.107.048520. Epub 2008 Jan 16.

4.

Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia.

Vāvere AL, Lewis JS.

Dalton Trans. 2007 Nov 21;(43):4893-902. Epub 2007 Sep 25.

PMID:
17992274
5.

Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.

Cherk MH, Foo SS, Poon AM, Knight SR, Murone C, Papenfuss AT, Sachinidis JI, Saunder TH, O'Keefe GJ, Scott AM.

J Nucl Med. 2006 Dec;47(12):1921-6.

6.

Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy.

Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, Hill RP, Koch CJ, Krishna MC, Krohn KA, Lewis JS, Mason RP, Melillo G, Padhani AR, Powis G, Rajendran JG, Reba R, Robinson SP, Semenza GL, Swartz HM, Vaupel P, Yang D, Croft B, Hoffman J, Liu G, Stone H, Sullivan D.

Int J Radiat Biol. 2006 Oct;82(10):699-757. Review.

PMID:
17118889
7.

Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models.

Tanaka T, Furukawa T, Fujieda S, Kasamatsu S, Yonekura Y, Fujibayashi Y.

Nucl Med Biol. 2006 Aug;33(6):743-50. Epub 2006 Jul 18.

PMID:
16934693
8.

Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).

Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW.

J Nucl Med. 2006 Jun;47(6):989-98.

9.

Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM.

Burgman P, O'Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC.

Nucl Med Biol. 2005 Aug;32(6):623-30.

PMID:
16026709
10.

Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.

O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn RD, Burgman P, Ruan S, Lewis JS, Welch MJ, Ling CC, Humm JL.

Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1493-502.

PMID:
15817355
11.

Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging.

Tai YC, Ruangma A, Rowland D, Siegel S, Newport DF, Chow PL, Laforest R.

J Nucl Med. 2005 Mar;46(3):455-63.

12.

Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging.

Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG, Krohn KA.

Clin Cancer Res. 2004 Apr 1;10(7):2245-52.

13.

Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.

Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, Mattfeldt T, Neumaier B, Reske SN, Hetzel M.

J Nucl Med. 2003 Sep;44(9):1426-31.

14.

Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG.

Obata A, Yoshimoto M, Kasamatsu S, Naiki H, Takamatsu S, Kashikura K, Furukawa T, Lewis JS, Welch MJ, Saji H, Yonekura Y, Fujibayashi Y.

Nucl Med Biol. 2003 Jul;30(5):529-34.

PMID:
12831991
15.

In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.

Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, Welch MJ, Siegel BA.

Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):844-50. Epub 2003 Apr 12.

PMID:
12692685
16.

Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.

Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ.

Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1233-8.

PMID:
12654432
17.

[(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.

Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, Chin LK, Hofstrand PD, Grierson JR, Eary JF, Krohn KA.

Eur J Nucl Med Mol Imaging. 2003 May;30(5):695-704. Epub 2003 Mar 11.

PMID:
12632200
18.

Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography.

Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, Wood DE.

Clin Cancer Res. 2000 Oct;6(10):3837-44.

19.

Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models.

Li CY, Shan S, Huang Q, Braun RD, Lanzen J, Hu K, Lin P, Dewhirst MW.

J Natl Cancer Inst. 2000 Jan 19;92(2):143-7.

PMID:
10639516
20.

Supplemental Content

Support Center